{
    "clinical_study": {
        "@rank": "60392", 
        "arm_group": [
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1/2 ml of dispensing alcohol administered orally at every 7 day for 5 month ."
            }, 
            {
                "arm_group_label": "Rhustoxicodendron 30", 
                "arm_group_type": "Active Comparator", 
                "description": "1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month."
            }
        ], 
        "brief_summary": {
            "textblock": "the purpose  of the study is to assess the safety and efficacy of  commonly used Homeopathic\n      medicine Rhustoxicodendron in 30 potency in the treatment of Rheumatoid arthritis."
        }, 
        "brief_title": "A Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis.", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "it is a multicenter phase 2 ,double blind study in patient with active Rheumatoid arthritis\n      ,there are 2 group in the study A and B ,where group A receive Rhustoxicodendron in 30\n      potency the first dose will administered orally (1/2 ml)after the completion of case taking\n      ,and repeated every 7th day for 5 month and on the other hand group B receive placebo orally\n      in (1/2 ml) at same interval for same period ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  those who will provide written consent to participate in the study\n\n          -  patient willing to turn up for 7th day follow up\n\n          -  patient who are willing and compliance to the study\n\n          -  those who are between 25 to 60 years .\n\n          -  patient who are willing and compliance to the study .\n\n          -  ESR more then 28 mm.\n\n        Exclusion Criteria:\n\n          -  Participating as a subject in any other clinical research study.\n\n          -  Children below the age of 25years.\n\n          -  Female subject who are pregnant or planning for pregnancy within 6 month.\n\n          -  History of seizures\n\n          -  Breast feeding women's.\n\n          -  Patient on treatment for life threatening illness like cancer aids etc.\n\n          -  Patient should not have any congenital abnormality or patient should not have\n             undergone any operative procedure as consequences of RA."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01905735", 
            "org_study_id": "SLSGB-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rhustoxicodendron 30", 
                "description": "1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.", 
                "intervention_name": "Rhustoxicodendron 30", 
                "intervention_type": "Drug", 
                "other_name": "poison ivy"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "dispensing alcohol"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "RA", 
        "lastchanged_date": "August 1, 2013", 
        "location": [
            {
                "contact": {
                    "email": "drseeniasharma@gmail.com", 
                    "last_name": "seenia sharma, B.H.M.S", 
                    "phone": "0091-7837144332"
                }, 
                "contact_backup": {
                    "email": "drmukeshkrsingh@gmail.com", 
                    "last_name": "mukesh k singh, B.H.M.S", 
                    "phone": "0091-9463131239"
                }, 
                "facility": {
                    "address": {
                        "city": "Ludhiana", 
                        "country": "India", 
                        "state": "Punjab", 
                        "zip": "141001"
                    }, 
                    "name": "Kochhar Clinic"
                }, 
                "investigator": [
                    {
                        "last_name": "seenia sharma, B.H.M.S", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "kuljinder kaur, B.H.M.S", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dr.mohitgupta@yahoo.in", 
                    "last_name": "mohit gupta, B.H.M.S", 
                    "phone": "0091-9212580805"
                }, 
                "facility": {
                    "address": {
                        "city": "Delhi", 
                        "country": "India"
                    }, 
                    "name": "Gupta Homoeo Clinic"
                }, 
                "investigator": [
                    {
                        "last_name": "mohit gupta, B.H.M.S", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "bhuwnesh goyal, B.A.M.S", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "prateek singh, B.H.M.S", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicentric,Double-blind,Placebo Controlled,Phase-2 Study to Assess the Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis .", 
        "overall_contact": {
            "email": "drseeniasharma@gmail.com", 
            "last_name": "seenia sharma, B.H.M.S", 
            "phone": "0091-7837144332"
        }, 
        "overall_contact_backup": {
            "email": "drmukeshkrsingh@gmail.com", 
            "last_name": "mukesh k singh, B.H.M.S", 
            "phone": "0091-9463131239"
        }, 
        "overall_official": [
            {
                "affiliation": "Healthcare Homoeo Charitable Society", 
                "last_name": "ravinder kochhar, MD hom", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "health care homoeo charitable society", 
                "last_name": "mukesh k singh, B.H.M.S", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "number of subject with ACR criteria improvement consisting of ACR 20,ACR50,ACR70 reduction in tender and swollen joint counts and 20%,50%,70% improvement respectively in 3 of the following 5 criteria .\nphysician global assessment of disease activity's.\npatient global assessment of disease activity's.\nsubject assessment of pain\nsubject assessment of function disability via health assessment questionnaire[HAQ]\nacute phase reactant ESR every 6 weeks upto 24 week", 
            "measure": "Number of subject With American College of Rheumatology (ACR) Criteria Improvement of at Least 20%, 50%, and 70% (ACR 20/50/70 Responders).", 
            "safety_issue": "No", 
            "time_frame": "6 weeks upto 24 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01905735"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Healthcare Homoeo Charitable Society", 
            "investigator_full_name": "ravinder kochhar", 
            "investigator_title": "principal investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "mean change from baseline in tender joint count.", 
                "safety_issue": "No", 
                "time_frame": "6 weeks upto 24 week"
            }, 
            {
                "measure": "mean change from baseline in swollen joint.", 
                "safety_issue": "No", 
                "time_frame": "6 weeks upto 24 week"
            }, 
            {
                "description": "mean change from baseline in physician assessment of disease activity via visual analog scale(0-100 mm)", 
                "measure": "mean change from baseline in physician global assessment of disease activity.", 
                "safety_issue": "No", 
                "time_frame": "every 6 weeks upto 24 week"
            }, 
            {
                "description": "mean change from baseline in patient global assessment of disease via visual analog scale(0-100 mm)", 
                "measure": "mean change from baseline in patient global assessment of disease .", 
                "safety_issue": "No", 
                "time_frame": "6 weeks upto 24 week"
            }, 
            {
                "measure": "mean change from baseline in subject assessment of pain using VAS from 0-100 mm", 
                "safety_issue": "No", 
                "time_frame": "6 weeks upto 24 week"
            }, 
            {
                "measure": "mean change from baseline in ESR", 
                "safety_issue": "No", 
                "time_frame": "6 weeks upto 24 week"
            }, 
            {
                "measure": "mean change from baseline in disability index of the health assessment Questionnaire (HAQ)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks upto 24 week"
            }
        ], 
        "source": "Healthcare Homoeo Charitable Society", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Healthcare Homoeo Charitable Society", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}